Type One Energy Issues First Realistic, Unified Fusion Power Plant Design Basis
27.3.2025 17:28:00 EET | Business Wire | Press release
Type One Energy announced today publication of the world’s first comprehensive, self-consistent, and robust physics basis, with conservative design margins, for a practical fusion pilot power plant. This physics basis is presented in a series of seven peer-reviewed scientific papers in a special issue of the prestigious Journal of Plasma Physics (JPP). They serve as the foundation for the company’s first Infinity Two stellarator fusion power plant project, which Type One Energy is developing for the Tennessee Valley Authority (TVA) utility in the U.S.
The Infinity Two fusion pilot power plant physics design basis realistically considers, for the first time, the complex relationship between competing requirements for plasma performance, power plant startup, construction logistics, reliability, and economics utilizing actual power plant operating experience. This Infinity Two baseline physics solution makes use of the inherently favorable operating characteristics of highly optimized stellarator fusion technology using modular superconducting magnets, as was so successfully proven on the W7-X science machine in Germany.
“Why are we the first private fusion company with an agreement to develop a potential fusion power plant project for an energy utility? Because we have a design anchored in reality,” said Christofer Mowry, CEO of Type One Energy. “The physics basis for Infinity Two is grounded in the knowledge of what is required for application to, and performance in, the demanding environment of reliable electrical generation for the power grid. We have an organization that understands this isn’t about designing a science project.”
Led by Chris Hegna, widely recognized as a leading theorist in modern stellarators, Type One Energy performed high-fidelity computational plasma physics analyses to substantially reduce the risk of meeting Infinity Two power plant functional and performance requirements. This unique and transformational achievement is the result of a global development program led by the Type One Energy plasma physics and stellarator engineering organization, with significant contributions from a broad coalition of scientists from national laboratories and universities around the world. The company made use of a spectrum of high-performance computing facilities, including access to the highest-performance U.S. Department of Energy supercomputers such as the exascale Frontier machine at Oak Ridge National Laboratory (ORNL), to perform its stellarator physics simulations.
“We committed to this ambitious fusion commercialization milestone two years ago and today we delivered,” said John Canik, Chief Science and Engineering Officer for Type One Energy. “The team was able to efficiently develop deep plasma physics insights to inform the design of our Infinity Two stellarator, by taking advantage of our access to high performance computing resources. This enabled the Type One Energy team to demonstrate a realistic, integrated stellarator design that moves far beyond conventional thinking and concepts derived from more limited modeling capabilities.”
The consistent and robust physics solution for Infinity Two results in a deuterium-tritium (D-T) fueled, burning plasma stellarator with 800 MW of fusion power and delivers a nominal 350 MWe to the power grid. It is characterized by fusion plasma with resilient and stable behavior across a broad range of operating conditions, very low heat loss due to turbulent transport, as well as tolerable direct energy losses to the stellarator first wall. The Infinity Two stellarator has sufficient room for both adequately sized island divertors to exhaust helium ash and a blanket which provides appropriate shielding and tritium breeding. Type One Energy has high confidence that this essential physics solution provides a good baseline stellarator configuration for the Infinity Two fusion pilot power plant.
“The articles in this issue [of JPP] represent an important step towards a fusion reactor based on the stellarator concept. Thanks to decades of experiments and theoretical research, much of the latter published in JPP, it has become possible to lay out the physics basis for a stellarator power plant in considerable detail,” said Per Helander, head of Stellarator Theory Division at the Max Planck Institute for Plasma Physics. “JPP is very happy to publish this series of papers from Type One Energy, where this has been accomplished in a way that sets new standards for the fidelity and confidence level in this context.”
Important to successful fusion power plant commercialization, this stellarator configuration has enabled Type One Energy to architect a maintenance solution which supports good power plant Capacity Factors (CF) and associated Levelized Cost of Electricity (LCOE). It also supports favorable regulatory requirements for component manufacturing and power plant construction methods essential to achieving a reasonable Over-Night Cost (ONC) for Infinity Two.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250327324853/en/
Contacts
Media Contact:
Andrea Schneibel, Communications Manager
Phone: +1 608-616-5965
E-mail: andrea.schneibel@typeoneenergy.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom